PD-1/L1

Exelixis
Biotech

Exelixis’ Cabometyx successor misses primary endpoint in CRC trial

While the zanzalintinib study is still technically positive, it could draw FDA scrutiny because Exelixis changed its primary endpoint twice.
Angus Liu Jun 22, 2026 3:40pm
Graphic of a fork in the road with arrows pointing in either direction
Favicon Fierce Pharma

Editor's Corner—Summit must submit to Big Pharma, stat

Sep 10, 2025 2:50pm
BioNTech

BioNTech, BMS tout first global data for PD-L1xVEGF drug in SCLC

Sep 8, 2025 11:00am
Tecentriq
Favicon Fierce Pharma

Roche touts Tecentriq biomarker win in bladder cancer

Aug 18, 2025 4:17pm
Graphic of a puzzle depicting both the US and Chinese flags with missing pieces bridging the two together

Pfizer CEO makes case for $6B bet on 'fabulous' bispecific

Jun 10, 2025 9:56am
photo of a pair of binoculars perched on a rock aimed at the rising sun

Are Lilly, Novartis eyeing the PD-1xVEGF field? Execs weigh in

Jun 4, 2025 1:00pm